+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Use of beta-lactamase-producing anaerobes to prevent ceftriaxone from degrading intestinal resistance to colonization

Use of beta-lactamase-producing anaerobes to prevent ceftriaxone from degrading intestinal resistance to colonization

Journal of Infectious Diseases 160(2): 274-280

Six adult volunteers were given 1 g/d of intravenous ceftriaxone for 5 d (consecutive). Ceftriaxone and beta-lactamase activities were assayed in fecal samples obtained before and during drug administration, and anaerobic bacteria, Enterobacteriaceae, and fungi were counted. In two volunteers, no fecal beta-lactamase activity was detected, but ceftriaxone was present during treatment at concentrations of 1.8-2.0 mg/g of feces. Concomitantly, fecal counts of anaerobes in these volunteers dropped from 10.5 to less than 8 log10 colony-forming units (cfu)/g of feces, and those of Candida species increased more than 100-fold. However, in the feces of the four other volunteers, beta-lactamase activity was high during ceftriaxone administration, but no ceftriaxone was detected. In these volunteers, ceftriaxone administration was not followed by any significant change in counts of anaerobes or Candida species. This appeared to be due to the intraintestinal hydrolysis of ceftriaxone by resident beta-lactamase-producing anaerobes. In gnotobiotic mice associated with a human fecal flora containing no beta-lactamase-producing anaerobes, it was possible to prevent the deleterious effects of ceftriaxone on intestinal microbial composition and on colonization resistance (against a strain of Candida albicans and one of ceftriaxone-resistant Enterobacter cloacae) by feeding the animals with an association of four beta-lactamase-producing anaerobic strains.

Please choose payment method:

(PDF emailed within 1 workday: $29.90)

Accession: 041915827

Download citation: RISBibTeXText

PMID: 2788196

Related references

Use of -Lactamase-Producing Anaerobes to Prevent Ceftriaxone from Degrading Intestinal Resistance to Colonization. Journal of Infectious Diseases 160(2): 274-280, 1989

Effects of imipenem-cilastatin, ertapenem, piperacillin-tazobactam, and ceftriaxone treatments on persistence of intestinal colonization by extended-spectrum-beta-lactamase-producing Klebsiella pneumoniae strains in mice. Antimicrobial Agents and ChemoTherapy 51(8): 3044-3045, 2007

Comparative activity of beta-lactamase inhibitors YTR 830, clavulanate, and sulbactam combined with beta-lactams against beta-lactamase-producing anaerobes. Antimicrobial Agents and ChemoTherapy 30(5): 789-791, 1986

Intestinal Colonization by Extended-Spectrum Beta-Lactamase-Producing Enterobacteriaceae in Infants. Revista de Investigacion Clinica; Organo del Hospital de Enfermedades de la Nutricion 67(5): 313-317, 2015

Comparison of antimicrobial resistance profiles among extended-spectrum-beta-lactamase-producing and acquired AmpC beta-lactamase-producing Escherichia coli isolates from Canadian intensive care units. Antimicrobial Agents and ChemoTherapy 52(5): 1846-1849, 2008

Fecal microbiota transplantation against intestinal colonization by extended spectrum beta-lactamase producing Enterobacteriaceae: a proof of principle study. Bmc Research Notes 11(1): 190, 2018

High rate of intestinal colonization with extended-spectrum-beta-lactamase-producing organisms in household contacts of infected community patients. Journal of Clinical Microbiology 46(8): 2796-2799, 2008

Epidemiology of bacterial colonization at intensive care unit admission with emphasis on extended-spectrum beta-lactamase- and metallo-beta-lactamase-producing Gram-negative bacteria--an Indian experience. Journal of Medical Microbiology 59(Pt 8): 955-960, 2010

Severe sepsis facilitates intestinal colonization by extended-spectrum-β-lactamase-producing Klebsiella pneumoniae and transfer of the SHV-18 resistance gene to Escherichia coli during antimicrobial treatment. Antimicrobial Agents and ChemoTherapy 58(2): 1039-1046, 2014

In vitro activity of ceftazidime-NXL104 against 396 strains of beta-lactamase-producing anaerobes. Antimicrobial Agents and ChemoTherapy 55(7): 3616-3620, 2011

Effect of pO-2 and pH on synergy of ceftriaxone and tazobactam against beta-lactamase producing enterobacteriaceae. Abstracts of the Interscience Conference on Antimicrobial Agents & Chemotherapy 34(0): 249, 1994

Detection of cfxA2, cfxA3, and cfxA6 genes in beta-lactamase producing oral anaerobes. Journal of Applied Oral Science 24(2): 142-147, 2016

Post antibiotic, post beta-lactamase inhibitor and post antibiotic sub-MIC effect of ceftriaxone/tazobactam on beta-lactamase-producing Escherichia coli in vitro. Sichuan Da Xue Xue Bao. Yi Xue Ban 40(6): 1071-1074, 2011

Emergence of clinical isolates of Escherichia coli producing Tem-1 derivatives or an Oxa-1 beta-lactamase conferring resistance to beta-lactamase inhibitors. Antimicrobial Agents and Chemotherapy 38(5): 1085-1089, 1994

Emergence of clinical isolates of Escherichia coli producing TEM-1 derivatives or an OXAl-1 beta-lactamase conferring resistance to beta-lactamase inhibitors. Antimicrobial Agents & Chemotherapy 38(5): 1085-1089, 1994